Zealand Pharma licenses GLP-1/gastrin peptide platform to Elvinix
Elvinix gains exclusive rights to develop the dual-acting peptide as a regenerative therapy aimed at restoring insulin production in type 1 diabetes.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 15 11:50 ETSource: Dealroom
The wire
- 01Zealand Pharma out-licensed its GLP-1/gastrin peptide platform to Elvinix for type 1 diabetes.
- 02Moves a beta-cell regeneration approach into a dedicated developer rather than a large obesity portfolio.
- 03Deal terms, development timelines and trial plans were not detailed in the announcement.
From the source
Read at news.google.comZealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy